The VA currently oversees 19 active psychedelic-therapy trials, backed by over $23 million in external funding, and conducts these studies in safe, controlled clinical settings with safety protocols aligned to FDA standards.

There is bipartisan legislative activity to expedite psychedelic therapies, including a May letter urging faster FDA action, even as FDA leadership has recently changed with the resignation of the agency’s commissioner.

President Trump has publicly supported expanding access to psychedelic therapies, signing an executive order aimed at speeding FDA evaluation and access for patients with major depressive disorder and substance use disorders, and coordinating among VA, FDA, and HHS.

The administration’s push to accelerate research on psychedelics is part of a broader effort to coordinate cross-agency action to facilitate treatment access for serious mental illness.

Key voices include VA Secretary Doug Collins, clinical advocates like Dr. Lynnette Averill, and perspectives from groups such as MAPS and Smart Approaches to Marijuana, highlighting a spectrum of safety, applicability, and policy views.

FDA has granted accelerated pathways related to psychedelic-assisted treatments as part of the broader push, signaling a faster regulatory track for promising therapies.

The trial emphasizes safety and adherence to federal guidelines, cautioning against self-medication and the substitution of psychedelics for proven, evidence-based treatments.

The Department of Veterans Affairs is advancing psychedelic therapy research for veterans, with MDMA trials already progressing and a new study for PTSD and alcohol use disorder launching at the VA Providence Healthcare System, enrolling about 80 veterans across Providence, Rhode Island and West Haven, Connecticut.

The trial carries a ClinicalTrials.gov identifier, and there is an expectation that FDA approval would be required before any public, non-research use of these therapies.

HHS and HHS Secretary Kennedy have voiced interest in creating controlled access pathways for military personnel with PTSD and depression to psychedelic therapies.

Regulatory and logistical hurdles are acknowledged, including sourcing ibogaine and the need for federal approval processes, alongside ongoing clinical and cost considerations for psychedelic treatments.

Enrollment for the new MDMA-assisted psychotherapy trial began in mid-May, employing randomized assignment between MDMA-assisted therapy and an active placebo, with rigorous safety and federal-guideline adherence.